b型流感嗜血杆菌结合疫苗3个批次的批间一致性、安全性和免疫原性:一项婴儿III期随机多中心研究结果
这项III期随机多中心研究评估了单价破伤风类毒素结合Hib疫苗(Hib-TT)与对照Hib-TT及联合Hib-TT疫苗相比的安全性和免疫原性,并分层评估3个Hib-TT批次的批间一致性和非劣效性。结果显示批间一致性未得到证实,Hib-TT在Hib和联用疫苗抗原免疫应答方面达到非劣效性统计标准,但在接种后抗PRP水平≥1µg/mL的参与者比例方面未达到,因分层设计非劣效性无法确立。Hib-TT在多数参与者中诱导了血清保护性抗体浓度,与常规儿童疫苗按3+1程序联用时耐受性良好。
要点
- 3个Hib-TT批次的批间一致性未得到证实。
- Hib-TT在Hib和联用疫苗抗原免疫应答方面达到非劣效性统计标准,但抗PRP≥1µg/mL比例未达到,非劣效性无法确立。
- Hib-TT在多数参与者中诱导血清保护性抗体,与常规儿童疫苗联用时耐受性良好。
核心结论
- Hib-TT在多数参与者中诱导了血清保护性抗体浓度,按3+1程序与常规儿童疫苗联用时耐受性良好。
- 批间一致性未得到证实,且因分层设计非劣效性无法确立。
研究设计与样本
- III期随机多中心研究(NCT01000974),评估单价破伤风类毒素结合Hib疫苗(Hib-TT)与单价Hib-TT对照疫苗及联合Hib-TT疫苗的比较。
- 分层评估3个Hib-TT批次的批间一致性及Hib-TT相对于Hib-TT对照疫苗的非劣效性。
- Hib-TT疫苗与常规儿童疫苗在2、4、6月龄(基础免疫)和15-18月龄(加强免疫)联用。
- 共入组4009名儿童,3086名完成加强免疫阶段。
主要发现
- 批间一致性未得到证实。
- Hib-TT在Hib和联用疫苗抗原的免疫应答方面达到非劣效性统计标准,但在接种后抗PRP水平≥1µg/mL的参与者比例方面未达到,因分层设计非劣效性无法确立。
- 基础免疫后92.5-96.7%和加强免疫后99.6-100%的参与者达到抗PRP水平≥0.15µg/mL;基础免疫后78.3-89.8%和加强免疫后97.9-99.1%的参与者达到抗PRP水平≥1µg/mL。
- 各组对联用疫苗的免疫应答和报告的不良事件发生率相当。
- 基础免疫后Hib-TT组、Hib-TT对照组和联合Hib-TT疫苗组分别记录到107/2963(3.6%)、24/520(4.6%)和21/520(4.0%)名儿童发生严重不良事件(SAE);加强免疫后分别记录到29/2337(1.2%)、4/435(0.9%)和2/400(0.5%)名儿童发生SAE;Hib-TT组中6/5330(0.1%)例SAE被认为与疫苗相关。
关键数值与推荐
- 原文未报告批间一致性的具体统计标准或阈值。
- 原文未报告非劣效性的具体界值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 批间一致性未得到证实。
- 因分层设计,非劣效性无法确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccination against Haemophilus influenzae type b (Hib) is included in routine pediatric immunization schedule in the United States. Previous vaccine shortages have created the need for additional options for Hib vaccination. METHODS: This phase III, randomized, multi-centered study (NCT01000974) evaluated the safety and immunogenicity of a monovalent tetanus toxoid-conjugate Hib vaccine (Hib-TT) compared to a monovalent (Hib-TT control) and a combination Hib-TT vaccine. We hierarchically assessed lot-to-lot consistency of 3 Hib-TT lots and non-inferiority of Hib-TT to Hib-TT control. We co-administered routine pediatric vaccines with Hib-TT vaccines at 2, 4, 6months (primary vaccination) and 15-18months of age (booster vaccination). We recorded adverse events (AEs) for 4 (solicited) and 31days (unsolicited) post-vaccination and serious AEs (SAEs) throughout the study. RESULTS: Of 4009 enrolled children, 3086 completed booster phase. Lot-to-lot consistency was not demonstrated. The study met statistical criteria for non-inferiority of Hib-TT to Hib-TT control in terms of immune responses to Hib and co-administered vaccines' antigens, but not in terms of participants achieving post-primary vaccination anti-PRP levels ≥1µg/mL. Because of the hierarchical nature of the objectives, non-inferiority could not be established. In all groups, 92.5-96.7% and 99.6-100% of participants achieved anti-PRP levels ≥0.15µg/mL, while 78.3-89.8% and 97.9-99.1% had anti-PRP levels ≥1µg/mL, post-primary and post-booster vaccination, respectively. Immune responses to co-administered vaccines and reported incidence of AEs were comparable among groups. We recorded SAEs for 107/2963 (3.6%), 24/520 (4.6%), and 21/520 (4.0%) children post-primary vaccination, and 29/2337 (1.2%), 4/435 (0.9%), and 2/400 (0.5%) children post-booster vaccination with Hib-TT, Hib-TT control and combination Hib-TT vaccine, respectively; 6/5330 (0.1%) SAEs in the Hib-TT groups were considered vaccine-related. CONCLUSION: Hib-TT induced seroprotective antibody concentrations in the majority of participants and was well-tolerated when co-administered with routine pediatric vaccines according to a 3+1 schedule.
引用
- Klein NP, Abu-Elyazeed R, Cornish M, et al. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. Vaccine. 2017. PMID: 28536030. doi:10.1016/j.vaccine.2017.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。